Altshuler Shaham Ltd Sells 35,149 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Altshuler Shaham Ltd decreased its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 22.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 124,681 shares of the company’s stock after selling 35,149 shares during the quarter. Altshuler Shaham Ltd’s holdings in Teva Pharmaceutical Industries were worth $1,311,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Blue Trust Inc. grew its stake in shares of Teva Pharmaceutical Industries by 92.3% during the fourth quarter. Blue Trust Inc. now owns 4,541 shares of the company’s stock worth $46,000 after purchasing an additional 2,180 shares during the period. Signaturefd LLC boosted its stake in Teva Pharmaceutical Industries by 90.8% during the 3rd quarter. Signaturefd LLC now owns 5,032 shares of the company’s stock worth $51,000 after acquiring an additional 2,394 shares during the last quarter. Desjardins Global Asset Management Inc. increased its stake in Teva Pharmaceutical Industries by 15.2% in the fourth quarter. Desjardins Global Asset Management Inc. now owns 8,123 shares of the company’s stock valued at $85,000 after purchasing an additional 1,070 shares in the last quarter. Schechter Investment Advisors LLC acquired a new stake in Teva Pharmaceutical Industries in the fourth quarter worth $117,000. Finally, DGS Capital Management LLC acquired a new position in Teva Pharmaceutical Industries in the fourth quarter valued at about $119,000. 54.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. The Goldman Sachs Group lifted their target price on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a “neutral” rating in a research report on Monday, February 5th. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 1st. Jefferies Financial Group raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and raised their price objective for the company from $10.00 to $14.00 in a research report on Tuesday, January 23rd. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price target for the company in a report on Friday, March 8th. Finally, Piper Sandler upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and upped their price target for the company from $12.00 to $19.00 in a research note on Monday, February 12th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $14.11.

Teva Pharmaceutical Industries Trading Up 1.7 %

NYSE:TEVA traded up $0.27 during mid-day trading on Thursday, hitting $16.01. 16,779,394 shares of the stock traded hands, compared to its average volume of 10,858,707. The stock has a market capitalization of $17.95 billion, a price-to-earnings ratio of -34.06, a PEG ratio of 1.67 and a beta of 1.04. Teva Pharmaceutical Industries Limited has a 52 week low of $7.09 and a 52 week high of $16.25. The firm’s 50 day moving average is $13.70 and its two-hundred day moving average is $11.72. The company has a quick ratio of 0.69, a current ratio of 1.02 and a debt-to-equity ratio of 2.23.

Insiders Place Their Bets

In other news, EVP Mark Sabag sold 100,000 shares of the company’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the completion of the sale, the executive vice president now owns 382,590 shares of the company’s stock, valued at $5,172,616.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Teva Pharmaceutical Industries news, EVP Mark Sabag sold 100,000 shares of the stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the completion of the sale, the executive vice president now directly owns 382,590 shares of the company’s stock, valued at approximately $5,172,616.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Eric Drape sold 9,815 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $13.12, for a total transaction of $128,772.80. Following the completion of the transaction, the vice president now owns 9,701 shares in the company, valued at $127,277.12. The disclosure for this sale can be found here. In the last ninety days, insiders sold 358,972 shares of company stock valued at $4,739,820. 0.55% of the stock is owned by insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.